secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0000950170-24-032513
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Q4 2023 net loss $30.8M; cash $336.9M; pipeline advances
---------------------------------------------------------------------------

- Net loss Q4 2023 $30.8M ($0.32/sh); full year net loss $101.7M ($1.08/sh).
- Cash $336.9M at Dec 31, 2023; plus $41.7M from Jan 2024 ATM; runway into late 2026.
- Four phase 1/2 trials ongoing; TNG908 clinical data expected 2024; first patient dosed for TNG348.
- FDA Orphan Drug Designation granted for TNG462 for soft tissue sarcomas.
- Appointed Chief Regulatory Officer, Chief Development Operations Officer, Chief Legal Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017024032513/0000950170-24-032513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017024032513/tngx-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-032513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer